Trial Profile
A Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB076 in Healthy Volunteers and Subjects With Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs BIIB 076 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Biogen
- 23 Mar 2020 Status changed from active, no longer recruiting to completed.
- 08 Nov 2019 Planned End Date changed from 14 Feb 2020 to 3 Mar 2020.
- 08 Nov 2019 Planned primary completion date changed from 14 Feb 2020 to 3 Mar 2020.